Seaport Res Ptn Weighs in on Hims & Hers Health, Inc.’s Q2 2024 Earnings (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) – Equities researchers at Seaport Res Ptn lifted their Q2 2024 earnings per share (EPS) estimates for shares of Hims & Hers Health in a research note issued on Monday, May 6th. Seaport Res Ptn analyst A. Kessler now anticipates that the company will post earnings per share of $0.05 for the quarter, up from their previous forecast of $0.02. Seaport Res Ptn currently has a “Buy” rating on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.11 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s FY2024 earnings at $0.19 EPS and FY2025 earnings at $0.37 EPS.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.02 by $0.03. The company had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business’s revenue was up 45.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.05) EPS.

HIMS has been the topic of several other research reports. SVB Leerink assumed coverage on Hims & Hers Health in a research note on Monday, February 26th. They set a “market perform” rating and a $10.00 price target on the stock. Piper Sandler upped their target price on Hims & Hers Health from $11.00 to $13.00 and gave the company a “neutral” rating in a report on Tuesday. Canaccord Genuity Group started coverage on Hims & Hers Health in a research report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price target for the company. Citigroup boosted their price objective on shares of Hims & Hers Health from $12.00 to $16.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, Jefferies Financial Group restated a “hold” rating and set a $15.00 target price (down from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Six equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $15.08.

Hims & Hers Health Trading Up 6.3 %

Shares of HIMS opened at $12.92 on Wednesday. Hims & Hers Health has a twelve month low of $5.65 and a twelve month high of $17.16. The firm has a market capitalization of $2.77 billion, a P/E ratio of -117.36 and a beta of 0.97. The firm’s 50-day moving average is $13.99 and its two-hundred day moving average is $10.41.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Belpointe Asset Management LLC increased its stake in Hims & Hers Health by 10.0% during the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after acquiring an additional 1,205 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Hims & Hers Health by 5.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after purchasing an additional 1,561 shares in the last quarter. Pathstone Family Office LLC raised its holdings in Hims & Hers Health by 2.8% in the third quarter. Pathstone Family Office LLC now owns 65,876 shares of the company’s stock valued at $414,000 after buying an additional 1,824 shares during the period. Swiss National Bank lifted its position in Hims & Hers Health by 0.7% during the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after buying an additional 2,000 shares in the last quarter. Finally, ProShare Advisors LLC grew its stake in Hims & Hers Health by 10.0% during the first quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock worth $344,000 after buying an additional 2,023 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, COO Melissa Baird sold 11,750 shares of the company’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $12.08, for a total value of $141,940.00. Following the completion of the transaction, the chief operating officer now directly owns 538,932 shares in the company, valued at $6,510,298.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Hims & Hers Health news, CEO Andrew Dudum sold 97,208 shares of Hims & Hers Health stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $9.58, for a total value of $931,252.64. Following the transaction, the chief executive officer now owns 51,653 shares in the company, valued at approximately $494,835.74. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Melissa Baird sold 11,750 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $12.08, for a total transaction of $141,940.00. Following the sale, the chief operating officer now directly owns 538,932 shares of the company’s stock, valued at $6,510,298.56. The disclosure for this sale can be found here. In the last three months, insiders sold 723,602 shares of company stock valued at $9,607,432. Company insiders own 31.63% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.